268 related articles for article (PubMed ID: 35008818)
1. Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein-Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design.
Kralj S; Jukič M; Bren U
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008818
[TBL] [Abstract][Full Text] [Related]
2. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
3. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
4. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
5. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
6. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.
Ton AT; Gentile F; Hsing M; Ban F; Cherkasov A
Mol Inform; 2020 Aug; 39(8):e2000028. PubMed ID: 32162456
[TBL] [Abstract][Full Text] [Related]
7. Structure based Drug Designing Approaches in SARS-CoV-2 Spike Inhibitor Design.
Shanmugam A; Venkattappan A; Gromiha MM
Curr Top Med Chem; 2022; 22(29):2396-2409. PubMed ID: 36330617
[TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
9. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
[TBL] [Abstract][Full Text] [Related]
10. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
[No Abstract] [Full Text] [Related]
11. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
12. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
[TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
El Hassab MA; Ibrahim TM; Al-Rashood ST; Alharbi A; Eskandrani RO; Eldehna WM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):727-736. PubMed ID: 33685335
[TBL] [Abstract][Full Text] [Related]
16. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
17. Prioritisation of Compounds for 3CL
Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
Molecules; 2021 May; 26(10):. PubMed ID: 34070140
[TBL] [Abstract][Full Text] [Related]
18. Docking Paradigm in Drug Design.
Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
[TBL] [Abstract][Full Text] [Related]
19. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
20. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds.
Zhang L; Howland M; Hilgenfeld R; Anderson MO; Eagon S
Bioorg Med Chem Lett; 2021 Jun; 41():127990. PubMed ID: 33775840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
